| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| STAT3 Transcription Factor | 12 | 2023 | 1121 | 1.600 |
Why?
|
| Interleukin-6 | 5 | 2011 | 1038 | 0.910 |
Why?
|
| GPI-Linked Proteins | 6 | 2013 | 223 | 0.910 |
Why?
|
| Janus Kinases | 2 | 2020 | 174 | 0.740 |
Why?
|
| Naphthols | 2 | 2017 | 25 | 0.700 |
Why?
|
| Fibrosis | 2 | 2020 | 793 | 0.700 |
Why?
|
| Pancreatic Neoplasms | 13 | 2013 | 5061 | 0.530 |
Why?
|
| Dendritic Cells | 5 | 2010 | 1085 | 0.510 |
Why?
|
| Cell Proliferation | 9 | 2017 | 7226 | 0.450 |
Why?
|
| src Homology Domains | 2 | 2023 | 124 | 0.410 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2011 | 62 | 0.390 |
Why?
|
| Sulfonamides | 2 | 2017 | 1823 | 0.370 |
Why?
|
| Inflammation | 1 | 2020 | 2522 | 0.360 |
Why?
|
| Cyclin E | 2 | 2008 | 267 | 0.350 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2020 | 1538 | 0.330 |
Why?
|
| NF-kappa B | 3 | 2013 | 1549 | 0.320 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2008 | 249 | 0.300 |
Why?
|
| Membrane Glycoproteins | 2 | 2008 | 1073 | 0.290 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 14289 | 0.280 |
Why?
|
| Cell Line, Tumor | 16 | 2021 | 14551 | 0.280 |
Why?
|
| Cyclophilin A | 1 | 2005 | 16 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 1493 | 0.260 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 1678 | 0.250 |
Why?
|
| Lipopolysaccharide Receptors | 4 | 2010 | 86 | 0.250 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2007 | 749 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 2054 | 0.240 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 334 | 0.230 |
Why?
|
| Cation Transport Proteins | 3 | 2010 | 199 | 0.230 |
Why?
|
| CD40 Ligand | 2 | 2017 | 115 | 0.230 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2007 | 1242 | 0.210 |
Why?
|
| Aspergillosis | 1 | 2024 | 246 | 0.210 |
Why?
|
| Genetics, Population | 4 | 2003 | 242 | 0.190 |
Why?
|
| Cytokines | 6 | 2024 | 2809 | 0.190 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 3976 | 0.190 |
Why?
|
| Cell Survival | 5 | 2017 | 3045 | 0.190 |
Why?
|
| Mucormycosis | 1 | 2022 | 108 | 0.190 |
Why?
|
| Interleukin-2 | 2 | 2024 | 842 | 0.190 |
Why?
|
| Signal Transduction | 4 | 2017 | 11965 | 0.180 |
Why?
|
| Apoptosis | 4 | 2016 | 7591 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 5437 | 0.180 |
Why?
|
| Enzyme Activation | 4 | 2017 | 1764 | 0.180 |
Why?
|
| S Phase | 2 | 2011 | 281 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 503 | 0.170 |
Why?
|
| Monocytes | 3 | 2007 | 788 | 0.170 |
Why?
|
| Prodrugs | 1 | 2020 | 217 | 0.160 |
Why?
|
| Tyrphostins | 2 | 2008 | 107 | 0.160 |
Why?
|
| Janus Kinase 2 | 2 | 2015 | 679 | 0.150 |
Why?
|
| Animals | 19 | 2024 | 59536 | 0.150 |
Why?
|
| Mice, Nude | 6 | 2016 | 4307 | 0.150 |
Why?
|
| CD40 Antigens | 1 | 2017 | 104 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 665 | 0.150 |
Why?
|
| Phosphorylation | 4 | 2020 | 4804 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 461 | 0.140 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2016 | 30 | 0.140 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 615 | 0.140 |
Why?
|
| Dioxolanes | 1 | 2015 | 41 | 0.140 |
Why?
|
| Blotting, Western | 5 | 2021 | 3536 | 0.130 |
Why?
|
| Neoplasms | 3 | 2020 | 15193 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 673 | 0.130 |
Why?
|
| RNA, Small Interfering | 3 | 2015 | 2216 | 0.130 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 268 | 0.130 |
Why?
|
| Platelet Activation | 1 | 2015 | 116 | 0.130 |
Why?
|
| Mice | 14 | 2024 | 34495 | 0.130 |
Why?
|
| Melanoma, Experimental | 1 | 2017 | 368 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2017 | 3821 | 0.130 |
Why?
|
| Platelet Aggregation | 1 | 2015 | 257 | 0.130 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1022 | 0.130 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 155 | 0.130 |
Why?
|
| Crohn Disease | 1 | 2018 | 351 | 0.130 |
Why?
|
| Synovial Membrane | 1 | 2014 | 41 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 566 | 0.120 |
Why?
|
| MicroRNAs | 3 | 2013 | 2947 | 0.120 |
Why?
|
| Receptors, KIR | 1 | 2014 | 62 | 0.120 |
Why?
|
| Morpholines | 2 | 2016 | 289 | 0.120 |
Why?
|
| Humans | 36 | 2024 | 261506 | 0.120 |
Why?
|
| DNA | 4 | 2023 | 2693 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 1586 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2015 | 8873 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2016 | 629 | 0.110 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 451 | 0.110 |
Why?
|
| Collagen | 1 | 2015 | 752 | 0.110 |
Why?
|
| Luciferases, Renilla | 1 | 2011 | 9 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 2 | 2013 | 1077 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 2359 | 0.100 |
Why?
|
| Coumarins | 1 | 2011 | 33 | 0.100 |
Why?
|
| DNA Primers | 2 | 2011 | 1399 | 0.100 |
Why?
|
| Cyclin A | 1 | 2011 | 47 | 0.100 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 421 | 0.100 |
Why?
|
| Chromones | 1 | 2011 | 120 | 0.100 |
Why?
|
| Tandem Repeat Sequences | 2 | 2002 | 201 | 0.100 |
Why?
|
| Gene Silencing | 3 | 2009 | 837 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 1070 | 0.100 |
Why?
|
| Lymphocyte Activation | 3 | 2020 | 1688 | 0.100 |
Why?
|
| Alleles | 4 | 2014 | 2437 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 987 | 0.100 |
Why?
|
| Microsatellite Repeats | 2 | 2003 | 575 | 0.090 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 3869 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2011 | 471 | 0.090 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 250 | 0.090 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2011 | 275 | 0.090 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2014 | 410 | 0.090 |
Why?
|
| RNA Interference | 2 | 2011 | 1408 | 0.090 |
Why?
|
| Norwalk virus | 1 | 2010 | 127 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2330 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2013 | 1064 | 0.090 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 533 | 0.090 |
Why?
|
| Genes, Reporter | 1 | 2011 | 798 | 0.090 |
Why?
|
| Protein Transport | 1 | 2011 | 734 | 0.090 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2010 | 194 | 0.090 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2017 | 1105 | 0.080 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 904 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2016 | 3005 | 0.080 |
Why?
|
| Cell Differentiation | 4 | 2007 | 4078 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 1450 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 621 | 0.080 |
Why?
|
| India | 5 | 2014 | 301 | 0.080 |
Why?
|
| Cholesterol Esters | 1 | 2007 | 34 | 0.080 |
Why?
|
| Foam Cells | 1 | 2007 | 27 | 0.080 |
Why?
|
| Immunotherapy, Active | 1 | 2008 | 46 | 0.080 |
Why?
|
| Base Sequence | 2 | 2011 | 4917 | 0.080 |
Why?
|
| Neuropilin-1 | 1 | 2007 | 40 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2326 | 0.080 |
Why?
|
| Thymosin | 1 | 2007 | 29 | 0.080 |
Why?
|
| Pentoxifylline | 1 | 2007 | 35 | 0.070 |
Why?
|
| Gene Expression | 2 | 2014 | 3570 | 0.070 |
Why?
|
| Culture Media, Conditioned | 1 | 2007 | 260 | 0.070 |
Why?
|
| Macrophages | 2 | 2010 | 1304 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2017 | 2027 | 0.070 |
Why?
|
| Basigin | 1 | 2006 | 20 | 0.070 |
Why?
|
| Cyclophilins | 1 | 2006 | 32 | 0.070 |
Why?
|
| Antigen Presentation | 1 | 2007 | 272 | 0.070 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 299 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2007 | 257 | 0.070 |
Why?
|
| Curcumin | 1 | 2006 | 117 | 0.070 |
Why?
|
| Stem Cells | 1 | 2013 | 1213 | 0.070 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 1215 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2006 | 287 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 2927 | 0.070 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 593 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 528 | 0.070 |
Why?
|
| Oncogene Proteins | 1 | 2006 | 354 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 4757 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 527 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 891 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2008 | 665 | 0.060 |
Why?
|
| Lentivirus | 1 | 2024 | 169 | 0.060 |
Why?
|
| Aspergillus fumigatus | 1 | 2024 | 135 | 0.060 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2022 | 1048 | 0.060 |
Why?
|
| Cell Line | 2 | 2015 | 5114 | 0.060 |
Why?
|
| Aspergillus | 1 | 2024 | 149 | 0.060 |
Why?
|
| Disease Models, Animal | 4 | 2022 | 7222 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2008 | 2084 | 0.050 |
Why?
|
| Melanoma | 1 | 2020 | 5317 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2008 | 1048 | 0.050 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 4557 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 5178 | 0.050 |
Why?
|
| Alkylation | 1 | 2021 | 29 | 0.050 |
Why?
|
| Tyrosine | 1 | 2023 | 498 | 0.050 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2021 | 95 | 0.050 |
Why?
|
| Surface Plasmon Resonance | 1 | 2021 | 105 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 1879 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2024 | 709 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 6942 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 1533 | 0.050 |
Why?
|
| Molecular Docking Simulation | 1 | 2021 | 144 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2020 | 1144 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 4849 | 0.050 |
Why?
|
| Pregnancy | 1 | 2013 | 7573 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2020 | 186 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 931 | 0.040 |
Why?
|
| Ligands | 1 | 2021 | 995 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2017 | 58 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2024 | 834 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5319 | 0.040 |
Why?
|
| Carcinoma | 1 | 2009 | 2578 | 0.040 |
Why?
|
| Superoxides | 2 | 2008 | 211 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2021 | 1487 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2017 | 5710 | 0.040 |
Why?
|
| Up-Regulation | 3 | 2010 | 2450 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 3639 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2017 | 173 | 0.040 |
Why?
|
| Cachexia | 1 | 2018 | 161 | 0.040 |
Why?
|
| Binding Sites | 1 | 2021 | 2171 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2014 | 1163 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 4 | 2003 | 3203 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2020 | 710 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 866 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 423 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2017 | 397 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2003 | 2086 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 2315 | 0.030 |
Why?
|
| Genotype | 2 | 2014 | 4109 | 0.030 |
Why?
|
| Octamer Transcription Factor-2 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Valosin Containing Protein | 1 | 2013 | 14 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 2 | 2008 | 848 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 657 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2013 | 84 | 0.030 |
Why?
|
| Caseins | 1 | 2013 | 63 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2014 | 460 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2013 | 250 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 11538 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 1459 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 986 | 0.030 |
Why?
|
| Lactation | 1 | 2013 | 210 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2014 | 842 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 7548 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2013 | 435 | 0.020 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2010 | 23 | 0.020 |
Why?
|
| Progesterone | 1 | 2013 | 513 | 0.020 |
Why?
|
| Viral Tropism | 1 | 2010 | 40 | 0.020 |
Why?
|
| Fucosyltransferases | 1 | 2010 | 76 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2009 | 5395 | 0.020 |
Why?
|
| Asthma | 1 | 2018 | 871 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2016 | 764 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2010 | 114 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 2010 | 102 | 0.020 |
Why?
|
| Female | 6 | 2020 | 141928 | 0.020 |
Why?
|
| ABO Blood-Group System | 1 | 2010 | 127 | 0.020 |
Why?
|
| Targeted Gene Repair | 1 | 2009 | 5 | 0.020 |
Why?
|
| Untranslated Regions | 1 | 2009 | 15 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 3443 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2008 | 5637 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 7789 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 677 | 0.020 |
Why?
|
| Interferon Type I | 1 | 2010 | 250 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 777 | 0.020 |
Why?
|
| Estrogens | 1 | 2013 | 751 | 0.020 |
Why?
|
| Anions | 1 | 2008 | 39 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2009 | 117 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3251 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2010 | 471 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 2314 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2007 | 4971 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6207 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 1618 | 0.020 |
Why?
|
| Cyclin D1 | 1 | 2010 | 576 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 2008 | 331 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2007 | 88 | 0.020 |
Why?
|
| Caliciviridae Infections | 1 | 2010 | 279 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 1987 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2008 | 265 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2007 | 6150 | 0.020 |
Why?
|
| RNA, Untranslated | 1 | 2009 | 237 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9244 | 0.020 |
Why?
|
| Virion | 1 | 2008 | 161 | 0.020 |
Why?
|
| Rats | 1 | 2016 | 6086 | 0.020 |
Why?
|
| Male | 6 | 2017 | 123000 | 0.020 |
Why?
|
| Virus Replication | 1 | 2010 | 709 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 3438 | 0.020 |
Why?
|
| Disease Progression | 2 | 2008 | 6682 | 0.020 |
Why?
|
| Biological Transport | 1 | 2007 | 597 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 3101 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 460 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 5159 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2006 | 344 | 0.020 |
Why?
|
| Antioxidants | 1 | 2007 | 507 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2013 | 2045 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 6100 | 0.020 |
Why?
|
| Lung | 1 | 2015 | 3151 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 2488 | 0.020 |
Why?
|
| Swine | 1 | 2008 | 1541 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 4113 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2017 | 3341 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2009 | 2074 | 0.010 |
Why?
|
| Oxygen | 1 | 2008 | 754 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2006 | 771 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 657 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2007 | 2307 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 5112 | 0.010 |
Why?
|
| Mutation | 1 | 2023 | 15179 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2508 | 0.010 |
Why?
|
| Transfection | 1 | 2008 | 2944 | 0.010 |
Why?
|
| Forensic Medicine | 1 | 2002 | 16 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 1555 | 0.010 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2013 | 1724 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 1363 | 0.010 |
Why?
|
| Software | 1 | 2009 | 1321 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2009 | 1616 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 4053 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 7702 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2007 | 3033 | 0.010 |
Why?
|
| Aged | 2 | 2017 | 70117 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2013 | 4821 | 0.010 |
Why?
|
| Cell Movement | 1 | 2008 | 2466 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 1323 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2007 | 935 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 3254 | 0.010 |
Why?
|
| Middle Aged | 2 | 2017 | 86204 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2009 | 9180 | 0.010 |
Why?
|
| Adult | 2 | 2014 | 77950 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 21713 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 37905 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 3578 | 0.010 |
Why?
|